

## CRITERIA FOR PRIOR AUTHORIZATION

Direct Acting Hepatitis C Agents

**PROVIDER GROUP** Pharmacy

**MANUAL GUIDELINES** The following drug requires prior authorization:  
Boceprevir (Victrelis®)

**CRITERIA FOR INITIAL PRIOR AUTHORIZATION** Must meet all of the following:

*\*Patients new to the plan will be allowed to continue previous hepatitis C regimen (max of 44 weeks of Victrelis therapy total)\**

- Patient must have a diagnosis of chronic hepatitis C
- Patient must have genotype 1 hepatitis C
- Patient must have stage 3 or 4 liver fibrosis
- Must be prescribed by or in consultation with a hepatologist, gastroenterologist, or infectious disease specialist
- Patient must be 18 years of age or older
- Victrelis must be used in combination with peginterferon alfa and ribavirin
- Female patients must have a negative pregnancy test within 30 days prior to initiation of therapy and monthly during treatment with Victrelis
- Patient must not have been on a previous or concurrent direct acting hepatitis C agent (i.e. concurrent therapy or previous trial with Victrelis, Incivek, Olysio, or Sovaldi)
- Dose must not exceed 12 capsules per day
- Patient must not have a history of illicit substance use or alcohol abuse within the past 6 months

**LENGTH OF INITIAL APPROVAL** 44 weeks

Ribavirin and Peginterferon alfa are approved when using triple therapy with Victrelis if Victrelis criteria are met

### DISCONTINUATION CRITERIA

- Provider must submit HCV RNA level after treatment week 12 and 24 within 7 days to prevent discontinuation of therapy
- Therapy will be discontinued if the HCV RNA level is above 100 IU/mL after treatment week 12 or if the HCV RNA level is detectable after treatment week 24